Too many copies of the HER2 gene or its overexpression appeared to cause an especially aggressive form of the disease. By the late ’90s, a drug called Herceptin that targeted the HER2 receptor, sped ...

HER2-positive breast cancers can be very aggressive. For several years, the drug Herceptin has been used to treat women with HER2-positive breast cancer that has metastasized or recurred.

The FDA has approved Amgen and Allergan’s biosimilar of Roche’s Herceptin, just in time for the breast cancer blockbuster’s patent expiry. Herceptin’s main US patent expires this month ...

Herceptin sales fell 11% to 1.38 billion Swiss francs ($1.5 billion) over the same period, while Perjeta’s 2024 sales dropped to 3.6 billion Swiss francs ($4 billion) versus roughly 3.8 billion ...

Ann Marie Rogers won a landmark victory to make the breast cancer drug Herceptin more widely available. Here, she explains what drove her. But others are asking if the treatment really lives up to ...

The new Herceptin formulation is now in phase 3 clinical trials, and if the program were successful, it would offer patients a convenient dosing form of the drug, which is currently given via ...

After six treatments, my oncologist managed to get an identical form of Herceptin for £400 cheaper. I managed to stay on that for a further few months until my oncologist gave me a telephone ...

Mundipharma has signed a deal with Celltrion to market a biosimilar of Roche’s Herceptin (trastuzumab) in seven European countries. Breast cancer blockbuster Herceptin earned $2.26 billion in ...